Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07063420

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers

Decision Support System (Software) for multi antidiabetic drug therapy use in type 2 diabetes (T2D).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Virginia Center for Diabetes Technology

Charlottesville, Virginia, 22903, United States

Location status: Recruiting

Location contact

Anas El Fathi, PhD

SUB_INVESTIGATOR

Daniel Cherñavvsky, MD

SUB_INVESTIGATOR

Mohammadreza Ganjiarjenaki

SUB_INVESTIGATOR

Ralf Nass, MD

CONTACT

[email protected]

About this study

The purpose of this study is to test the safety and feasibility of using a patient centered decision support system (software) aim for healthcare providers to treat people with type 2 diabetes under multi antidiabetic drug therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18.0 years old at time of consent.
  • Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months.
  • Hemoglobin A1c (HbA1c) ≥ 7.0%.
  • Currently using an approved long-acting insulin for at least 3 months (e.g., insulin glargine, insulin degludec).
  • Treated or about to be treated with multi-drug therapies for T2D.
  • If using a CGM, willingness to wear an additional study CGM during the duration of the study.
  • Access to the internet and willingness to upload data during the study as needed.
  • If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females who self-report that they are of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.

Exclusion criteria

  • Currently using rapid insulin for at least three months (e.g., insulin aspart, insulin lispro, insulin regular).
  • Currently being treated for a seizure disorder.
  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples:
  • Seizure disease
  • Decompensated cardiac disease
  • Inpatient psychiatric treatment in the past 6 months
  • Presence of a known adrenal disorder
  • Currently pregnant or intent to become pregnant during the trial.
  • Anticipated surgical, interventional procedures or prolonged periods of fasting during this study.

Treatment and study plan

Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS)

Other

Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS) PCM-DSS

Continuous Glucose Monitor (CGM) + Usual Care

Other

Continuous Glucose Monitor (CGM) + Usual Care (Physician)

Primary outcomes

  1. Clinical efficacy

    Time frame: 22 weeks

    Measured by improved glycemic control (HbA1c change and CGM-derived metrics).

Other outcomes

  1. Patient satisfaction

    Time frame: 22 weeks

    Patient satisfaction which will be assessed through Diabetes Distress Scale Survey (DDS) questionnaire, measured after Screening and at End of Study, and the Participant Satisfaction Survey (PSS) measured at End of Study. DDS asks the participant to consider the degree distress they felt to 17 items during the past month. PSS is six questions asking the participant about the experience in this study.

Study contacts

Contact information is provided by the study sponsor or research team.

Carlene Alix

CONTACT

[email protected]

(434) 249-8961

Laura Kollar, RN

CONTACT

[email protected]

(434) 982-6479

Sponsors and collaborators

Lead sponsor

Daniel Chernavvsky, MD

Other

Collaborators

  • University of Virginia

Registry information

Official study title

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers: A Pilot Study

Acronym: TREAT2D

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 14, 2025
Registry last updated
Nov 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.